Mastocytosis is a clonal neoplasm with the potential to affect various organs within the body. It can range in clinical severity from benign to extremely aggressive. Mastocytosis can be separated into cutaneous, systemic, and leukemic forms, as well as mast-cell sarcoma and extracutaneous mastocytoma. It is most often an acquired condition but can be inherited; the most commonly identified genetic aberrations leading to mastocytosis are activating mutations involving codon 816 of the KIT gene. Herein, we present the case of a 30-year-old Caucasian man with systemic mastocytosis discovered to have a p.Arg634Trp mutation involving KIT. To our knowledge, this mutation has previously only been identified in children with familial urticarial pigmentosa. Ours is the the first case report in the literature of an adult with systemic mastocytosis likely due to a p.Arg634Trp KIT mutation.
expressed by hematopoietic stem cells and mast cells, among other cells within the body. SCF-KIT signaling plays an important role in mast-cell differentiation, proliferation, and functioning. 2 Various activating mutations within KIT have been associated with systemic mastocytosis, with p.Asp816Val (D816V) being the most common, occurring as a sporadic mutation in greater than 80% of adults with systemic mastocytosis. 1, 3, 4 Familial mastocytosis, in contrast, typically arises in children with cutaneous mastocytosis and has been associated with several other mutations in KIT. [5] [6] [7] [8] [9] [10] [11] KIT mutations have also been associated with an entity known as familial gastrointestinal stromal tumors and mastocytosis. 12, 13 Recently, 3 siblings with urticaria pigmentosa were reported to have a mutation in exon 13 leading to a p.Arg634Trp (R634W) amino-acid substitution. 14 Herein, we report the first case in the literature, to our knowledge, of an adult patient with apparent systemic mastocytosis, who was ultimately discovered to harbor a KIT p.Arg634Trp mutation.
Case Report
A 30-year-old Caucasian man presented with a skin rash that he reported having had since childhood. In the past, certain healthcare professionals had told him that the rash was present due to urticaria pigmentosa; no biopsy had ever been performed. 15 is uncertain. Based on the overall clinical and pathologic findings, the diagnosis of indolent systemic mastocytosis was made. Further workup included an abdominal ultrasound, which showed a normal-sized liver; a spleen measurement of 13 cm (at the upper limit of the normal value), and a bone density study for which the results were normal. The patient was prescribed cromolyn sodium, famotidine, and cetirizine, which provided him relief from his symptoms. He was given an epinephrine autoinjector to carry at all times and instructed to wear a medical bracelet stating his diagnosis.
Conclusion
The World Health Organization (WHO) criteria for systemic mastocytosis include 1 major and 4 minor criteria, of which 1 major and 1 minor or 3 minor criteria should be met for the diagnosis 16 ( Table 1 ). The patient in this case fulfilled the major criterion of multifocal aggregates of mast cells and the minor criterion of mast cells coexpressing CD117 and mastcell tryptase with CD2(dim) and CD25. Overtly atypical or spindled morphologic findings were not observed, and the serum total tryptase level was elevated but not greater than 20 ng per mL and was not evaluated for persistence. Although a KIT mutation was identified, it was not at codon 816 and therefore, it technically does not fulfill this minor criterion. Overall, the major criteria and 1 minor criterion were fulfilled, consistent with a diagnosis of systemic mastocytosis.
Herein, we report the first case in the literature of an adult patient with a p.Arg634Trp KIT mutation associated with systemic mastocytosis. To our knowledge, the only other report of this mutation leading to mastocytosis is one that reported 3 pediatric siblings with familial urticaria pigmentosa. 14 Based on the adult patient's history of rashes since childhood and peripheral blood KIT mutation allele frequency that suggested a germline mutation, the patient likely has a familial form of the condition. However, to the patient's knowledge, none of his family members, including 3 siblings and many cousins, display similar symptoms; this information raises the possibility of a de novo mutation. Testing family members for this mutation may be helpful for investigating this possibility.
The c.1900C > T variant leading to p.Arg634Trp has been listed in the Catalogue Of Somatic Mutations In Cancer (COSMIC) database 3 times, including 2 germ cell tumors and an acute myeloid leukemia (http://cancer.sanger.ac.uk/ cosmic/mutation/overview?id¼1600403). This mutation is within a tyrosine kinase domain and, like several other KIT mutations identified in neoplasms, is likely an activating mutation that induces cellular proliferation; however, this hypothesis remains to be tested. Databases such as COSMIC are extremely helpful for identifying previously reported genetic variants but are far from comprehensive; therefore, efforts to incorporate identified variants into such databases is highly encouraged.
Regarding therapy, specific KIT mutations have been shown to confer sensitivity or resistance to imatinib mesylate, 17 but the effectiveness of this tyrosine kinase inhibitor in patients with the p.Arg634Trp mutation is unknown. As more patients with mastocytosis who harbor KIT mutations are characterized, we will find it interesting to learn which mutations confer better or worse prognosis, as well as differential responses to therapy. The WHO currently only include mutations affecting codon 816 as a diagnostic criterion for systemic mastocytosis. However, the addition of KIT mutations other than those affecting codon 816 to the WHO diagnostic criteria should be considered. Finally, the diagnosis of familial mastocytosis should be considered even in older patients presenting for evaluation, particularly those with a history of lifelong urticarial rashes. Such diagnoses may be confirmed by molecular analysis, as performed in this study. LM
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